

Neurosurgery for mental disorder

George W Fenton

Ir J Psych Med 1998; 15(2): 45-48

Origins of neurosurgery for mental disorder

At the historic second Neurological Congress held at University College, London (July 29 - Aug 5, 1935), where Pavlov, aged 86, gave a valedictory review of his life's work, a symposium on the Frontal Lobes took place. Fulton from Yale presented frontal lobectomy studies on two chimpanzees, Becky and Lucy carried out in collaboration with his colleague Jacobson. The major finding was that the manifestations of 'frustration' induced by delayed response tasks of increasing difficulty were abolished by bilateral frontal ablation with resulting calmness and passivity. Egas Moniz, the 59 year old professor of neurology in Lisbon, was the first discussant of Fulton's paper, pointing out its potential application to psychiatry. Born Antonio Caetano in northern Portugal, he adopted the pen name Egas Moniz, a Portuguese military hero of the 12th century who led his countrymen to end the Muslim invasion of Portugal. He was an active liberal and republican during the reactionary monarchy of the time. The monarchy was overthrown and a republic proclaimed in 1911, the year Moniz was appointed to the Lisbon Chair of Neurology. Between 1914 and 1918 he served the new government as Ambassador to Spain and later as Foreign Minister, taking time from his diplomatic duties to write a textbook on the neurology of brain injury. He returned to neurology at the end of the first World War, when the liberal government was replaced by a conservative one. Between 1927 and 1935, he developed cerebral angiography.

After the second neurological congress, he returned to Portugal determined to apply Fulton and Jacobson's techniques to intractably disturbed psychiatric patients. With the collaboration of a young neurosurgeon Lima, the first psychosurgery operations were performed on November 12, 1935, in Lisbon. Four patients, two with chronic depression and two with paranoid schizophrenia, were operated on. Within the next year, they had completed 20 operations, initially using alcohol injections into the depths of each frontal lobe and later a special instrument called a leucotome manufactured in Paris. They reported the clinical outcome as recovery in seven, improvement in seven and no change in six patients.¹ Subsequently Moniz had difficulty in recruiting cases because of the hostility of the local psychiatric establishment. An excellent review of the early days of psychosurgery is given by Shutts.²

The lobotomy era

Meanwhile, Walter Freeman, a neuropathologist and neurologist at George Washington University, USA, collaborated with James Warts, a neurosurgeon who had previously done experimental neurophysiology with

Fulton. They developed the prefrontal leucotomy. In this operation a burr hole was made in each temporal region through which a leucotomy knife was swept up and down in an arc, severing the frontal cortical-subcortical connecting white matter and making large lesions of variable size.³ The blind 'freehand' operation and its many modifications were used over the next 20 years. The transorbital leucotomy technique developed by Freeman was widely used and particularly controversial. This psychosurgery variant did not require neurosurgical skill and involved penetrating the roof of each orbit with a sharp instrument like an ice pick, angled upwards and backwards and rotated laterally on each side to make the cut. Freeman used to anaesthetise the patients with ECT prior to carrying out the operation in a range of non-surgical settings! Prefrontal leucotomy and related psychosurgical procedures were carried out widely in the western world.⁴ Even in the early days their use was a source of controversy since mind altering surgery was regarded as unethical by many psychiatrists, especially those with a psychoanalytic background.

The mortality was surprisingly low (0.3%) considering the blind nature of the surgery. The incidence of post operative epilepsy was 1.3%. More serious was the 3% prevalence of severe frontal lobe syndrome and less extreme but still serious personality defects in perhaps as many as one third of patients. These adverse complications greatly added to the controversy about the ethics of such surgery. The cavalier attitudes of many of its early practitioners towards selection and assessment of patients and uncritical claims about efficacy also added fuel to the storm of criticism

What has tended to be overshadowed by the ethical debate concerning the early operations is their relative clinical efficacy in the era before effective psychotropic medication. In a review of 9,284 patients operated on in England and Wales between 1942 and 1954, 41% were recovered or greatly improved, 28% minimally improved, 25% unchanged, 2% worse and 4% died.⁵ Two-thirds of those operated on had a diagnosis of schizophrenia and one third affective disorder. Of the latter 63% were recovered or greatly improved, compared to 30% of the former.

Modified operations

The next step in the evolution of psychosurgery was made possible by Fulton.⁶ He carefully analysed the extent and site of the lesions at post-mortem examination. By relating the latter findings to clinical outcome, he was able to demonstrate that lesions confined to ventromedial quadrants of the frontal lobes gave the best clinical results with the lowest risk of serious personality change. This led to open brain surgery with the lesions restricted to the ventromedial quadrants of the frontal lobe or related areas. The most popular operation of this period was the bimedial leucotomy. By the mid 1950s the introduction of

George W Fenton, Department of Psychiatry, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland.

SUBMITTED: OCTOBER 20, 1997. ACCEPTED: JANUARY 28, 1998

antipsychotic drugs provided an effective medical treatment for the positive symptoms of schizophrenia and psychosurgery was no longer an indication in this condition. In addition, follow-up of both the standard and restricted lesions operations has shown that patients with intractable depressive, anxiety or obsessive-compulsive disorders had a consistently better outcome than schizophrenic patients.

Stereotactic neurosurgery

The advent of stereotactic neurosurgery provided neurosurgeons with the capacity to make precisely localised lesions. There is no consensus on the optimum target site for the operation but the aim in most procedures is to interrupt the limbic system circuits at a convenient site usually in the orbitomedial frontal cortex, anterior limbs of the internal capsule or cingulate areas.

Sites of stereotactic lesions

Geoffrey Knight pioneered the stereotactic subcaudate tractotomy (SST) operation to simulate the open freehand orbital undercut procedure which had to be abandoned because of a high prevalence of epilepsy. In the initial SST operation, lesions were made deep in the frontal lobes in the subcaudate areas using radioactivity from arrays of implanted ceramic rods containing radio-yttrium (⁹⁰Y) which has a half life of about 68 hours. This proved a safe technique and well over 1,000 operations have been performed in London by Knight and his successors.⁷ Since radio-yttrium is no longer readily available, similar lesions in the same sites are now made by electro-coagulation.

In Sweden, the anterior limbs of each internal capsule have been targeted, an operation known as a bilateral anterior capsulotomy.⁸ The lesions are usually thermal, though a gamma knife technique is now being pioneered in Sweden and USA. In contrast, the anterior cingulotomy operation targets the cingulate tracts on each side.⁹ Finally, the limbic leucotomy procedure involves lesions in both the orbitomedial quadrants of each frontal lobe and the cingulate areas on each side.¹⁰ It has been suggested that depression is best treated by lesions in the basomedial frontal region (ie. SST or cingulotomy), while OCD responds best to capsulotomy operations. More rigorous evidence is required to substantiate this claim. Studies directly comparing the effect of the different target sites on clinical outcome have yet to be carried out.

Acute complications of stereotactic surgery

All these operations have in common an operative mortality of less than 0.1% and a low prevalence of immediate and long-term adverse effects. Like all operations on the brain, haemorrhage and/or infection are acute risks with hemiplegia in less than 0.3%. More benign post-operative complications are transient confusion, lethargy and incontinence of urine which may persist for a few days or weeks post-operatively. Reduced tolerance to maintenance psychotropic medication carried on unchanged over the post-operative period seems a significant factor in the development of confusion. Transient post-operative oedema is another factor.

Longer term complications

In the longer term, epilepsy is a significant complication; between 1% and 2% for the SST and the capsulotomy

operations and a higher prevalence of 9% for the cingulotomy procedure. The seizures are usually few in number, infrequent in recurrence and responsive to anti-epileptic medication. The frontal lobe syndrome is a very rare but not unknown complication of the stereotactic operations.^{11,12} Personality trait changes such as 'outspokenness', disinhibition, irritability, lack of consideration and lack of initiative, have been described after surgery. None have been regarded as socially incapacitating and some indicate changes in psychosocial adjustment rather than organic deficits. Some reflect mental state improvements following surgery, eg. improved mood leading to more assertiveness and less dependence. Others mark a return to pre-morbid functioning styles. Indeed, the only two long-term systematic studies of personality change after surgery report that in the majority of patients there was no significant negative impact on personality. In fact, there were improvements in mood, depth of feeling, anxiety proneness, obsessiveness, sociability and level of dependency.^{13,14}

In particular there were no significant changes in measures of impulsivity or hostility. A 1988 review of 834 stereotactic operations reported marked personality change in 0.4% and mild personality change in 3%.¹⁵ General intelligence, cognitive processing speed, attention and memory show no long-term deficits, though in one of the long-term studies OCD patients operated on had a significantly poorer performance on the Wisconsin Card Sorting Test, a test of frontal lobe functioning.¹² In contrast 23 depressed patients who underwent SST showed no deficits in frontal lobe functioning.¹⁶

Contemporary indications

The main contemporary indications for stereotactic neurosurgery are chronic treatment refractory major depressive disorder and obsessive-compulsive disorder. Despite the advances in the medical and psychological therapies for these conditions, there seems to be a residual number of treatment resistant patients for whom NMD is an appropriate treatment option when other potentially effective therapeutic strategies have failed. A 1994 survey of Scottish psychiatrists covering a population of five million estimated 195 such patients seen over the previous five years, at least 10 times greater than the number actually assessed. In the UK as a whole, the number of operations has averaged 23 a year in the 1990 to 1994 period, over 70% having been SST procedures performed at the Geoffrey Knight unit in London, now relocated from the Brook to Kings College Hospital. Other UK centres are Cardiff, Leeds, the Atkinson's Morley Hospital London, and Dundee, which is the national Scottish centre.

Efficacy of stereotactic neurosurgery

The clinical efficacy of NMD is difficult to evaluate. Ethical issues make randomised controlled trials difficult, if not impossible, to organise. The various centres use different stereotactic targeted lesions and there are no comparative studies examining the relative efficacies of the various techniques. The distribution of the clinical diagnoses of the patients operated upon varies between centres as well as the nature and scientific rigour of assessment instruments, making comparison difficult. Long-term outcome studies (with post operative follow-up periods of 10 years or more) contain small sample sizes. Clinical

Released from depression Reunited with the world

Edronax^{4mg bid}
reboxetine tablets



Pharmacia
& Upjohn

EDRONAX® ABBREVIATED PRESCRIBING INFORMATION: **Presentation:** Tablets containing 4mg reboxetine. **Indications:** Use in the acute treatment of depressive illness, and maintenance of clinical benefit in patients responsive to treatment. **Posology and method of administration:** *Adults* 4 mg b.i.d. (8 mg/day) administered orally. After 3-4 weeks, can increase to 10 mg/day. *Elderly and children* Elderly patients have been studied in comparative clinical trials at doses of 2 mg b.i.d., although not in placebo controlled conditions. There is no experience in children and therefore reboxetine cannot be recommended in either of these groups. *Renal/Hepatic Insufficiency* 2 mg b.i.d. which can be increased based on patient tolerance. **Contra-indications:** Hypersensitivity to the compound or its constituents. Use in pregnancy/lactation. **Special warnings and precautions for use:** Close supervision is required for subjects with a history of convulsive disorders and must be discontinued if the patient develops seizures. Avoid concomitant use with MAO-inhibitors. Close supervision of bipolar patients is recommended. Close supervision should be applied in patients with current evidence of urinary retention, glaucoma, prostatic hypertrophy and cardiac disease. At doses higher than the maximum recommended, orthostatic hypotension has been observed with greater frequency. Particular attention should be paid when administering reboxetine with other drugs known to lower blood pressure. **Interactions with other medicaments and other forms of interaction:** Reboxetine should not be co-administered with macrolide antibiotics, fluvoxamine, azole anti-fungal agents. Caution when co-administered with drugs that have a narrow therapeutic margin and are metabolised by CYP3A4 or CYP2D6 e.g. anti-arrhythmics (flecainide), anti-psychotic drugs and tricyclic anti-depressants. No pharmacokinetic interaction with lorazepam. Reboxetine does not appear to potentiate the effect of alcohol. **Pregnancy and lactation:** Reboxetine is contraindicated in pregnancy and lactation. **Effects on ability to drive and use machines:** Reboxetine is not sedative per se. However, as with all psychoactive drugs, caution patients about operating machinery and driving. **Undesirable effects:** Adverse events occurring more frequently than placebo are: dry mouth, constipation, insomnia, paraesthesia, increased sweating, tachycardia, vertigo, urinary hesitancy/retention, impotence. **Overdose:** Monitor cardiac function and vital signs. General symptomatic supportive and/or emetic measures might be required. **Package and GMS Price:** Pack of 60 tablets in blister. **Published online by Cambridge University Press** **Marketing Authorisation Holder:** Pharmacia & Upjohn Limited, Davy Avenue, Milton Keynes, MK5 8PH UK. **Marketing Authorisation Number:** PA 16/58/2. **Date of Preparation:** April 1998. Edronax® is a registered trademark. 98/05/ED4.

outcome is rarely assessed by raters independent of the NMD team

Nevertheless, there are now a number of well documented published studies from centres in Sweden, UK, USA and Australia using reliable and valid measures of mental state and behaviour. In several, comparison with small samples of age and gender matched patients suffering from the same disorder but not operated upon have been possible. A literature review on clinical effectiveness is published in the Scottish Office report (1996).¹⁷ For both major depressive and obsessive-compulsive disorder, between one third and two thirds of patients are in the Pippard rating scale A and B categories (recovered; much improved or showing considerable symptom alleviation). The median percentage of patients showing significant improvement is around 50%. An exception is the Bristol study of 142 OCD patients followed-up for 15-20 years.¹⁸ Of these 68% showed complete recovery or marked improvement. Gold electrodes were implanted in the orbital and paracingulate areas of the frontal lobe and left in place for up to 10 months in 72 subjects. Electrical stimulation and subsequently electrocoagulation was progressively carried out until the optimum response was reached. These procedures were performed during a prolonged inpatient stay with intense psychological support and behavioural therapy, which may have contributed to the impressive outcome. This operation is no longer carried out. It was the brain child of Harry Crow, neuropsychiatrist at the Burden Neurological Hospital, and did not outlast his retirement.¹⁹ In any event, inpatient stays of up to 10 months at a time do not fit in with the aegis of the new NHS!

Another observation that supports the relatively favourable follow-up study data is comparisons with the suicide rates following neurosurgery. Compared to the 15% suicide rate for non-surgically treated patients with chronic major depressive disorders, the suicide rates in the years following neurosurgery are much lower; 1% for SST, 5% for limbic leucotomy, 9% for cingulotomy. The total lack of suicides following capsulotomy may relate to the fact that capsulotomy has been used more often for OCD patients than for depressed patients. Nevertheless, for the above mentioned reasons, the follow-up outcome data remains unsatisfactory, and open to challenge from sceptics. A recent editorial²⁰ calling for better evaluation of NMD has suggested five requirements for such an assessment. These are as follows:

1. Independent assessment by mental health workers who had no role in the decision making and who have different professional backgrounds; through audio taping or video taping of interviews before surgery and at follow up for further independent evaluation.
2. Clear pre-operative and post-operative information and psychometric tests assessing aspects of both symptom severity and cognitive function.
3. An adequate period following the intervention of at least a year before follow-up.
4. Information from brain imaging before and after surgery in order to establish the location and extent of the stereotactic lesions. The fact that different centres use different stereotactic techniques adds to the confusion. However, if the various centres can be persuaded to use a common pre- and post-operative assessment protocol, then it should be possible to do comparative studies examining the efficacy of different techniques.

5. A complete sample of patients, not just those who are willing and able to travel to take part in a clinic-based follow-up. This requires home based evaluation.

Who should carry out neurosurgery for mental disorder?

It is best carried out in specialist centres where a multi-disciplinary team of psychiatrists, a neurosurgeon and a clinical psychologist with a special interest in these disorders, who can work together to carry out the assessment of suitability for this type of surgery, the pre-operative assessments, the surgery itself and subsequent follow-up.

The selection for surgery requires confirmation of the diagnosis, the establishment of chronicity (five years or more continuous illness) and the treatment refractory nature of the disorder according to a standard protocol of available treatments, both physical and psychological. The patient, their next-of-kin and carers need to be fully informed about the advantages and disadvantages of surgery by one or more members of the multidisciplinary team and be given the opportunity to discuss these issues not only with members of the multidisciplinary team but with their friends and usual carers.

Communication can be facilitated with the use of an information sheet written in simple language describing the nature of the operation, the reasons for using it, possible complications and predicted outcome. Preparing information in this way facilitates the development of informed consent. One such initial consent is obtained, it is necessary to involve the statutory bodies that deal with the protection of patients' interests; Mental Health Act Commission in England and the Mental Welfare Commission in Scotland. Their consent is mandatory in England. In Scotland the Mental Welfare Commission is required by law to give consent in a case of detained patients only, but an informal arrangement exists for them to assess other patients and give their opinion about suitability for surgery.

A number of baseline assessments of mental state, social adjustment, personality, quality of life and cognitive function are required before the operation, with standard videotape recording of mental state. MRI scanning is also necessary prior to surgery.

Post-operative management

Physical recovery from surgery is rapid (within a few days). The standardised assessments of mental state can be repeated at this stage and the rehabilitation programme initiated. Patients are actively encouraged to follow a graded programme of occupational and social activities. An important aspect is that there is often a slow response to the operation. Although some patients manifest a dramatic improvement shortly after the operation, the majority pursue a gradual and varying rate of recovery over a period of up to six to 12 months after surgery. It is essential therefore to organise a continuing active rehabilitation programme for all patients, which should continue after return to their base hospitals 10 days to two weeks after surgery.

Paradoxically, the significant improvements in mood and mental state following lead to increased independence and assertiveness and place strains on the family relationships, especially when family members have been used to having a chronically depressed and therefore submissive quiet and dependent person to care for. Such changes can be challenging for family and friends to adjust to. Equally,

the patient may have difficulties in adjusting to independent living after having been used to years of dependence upon other people. Such issues need to be identified by the mental health team responsible for the patient's long-term aftercare, and dealt with.

Another factor to take account of is that relapses in mental state occur months and/or years following surgery, even in a patient who has a relatively successful outcome. These need to be treated effectively by conventional methods. The patient needs to be reassured that such lapses do not necessarily mean a return to the chronicity of the preoperative condition. Indeed, it is worthy of comment that patients after surgery often respond better to physical treatments such as ECT and antidepressant drugs, as well as psychological treatments such as cognitive therapy.

Conclusion

Just over 60 years after its introduction, psychosurgery in modern dress known as Neurosurgery for Mental Disorder (NMD) continues to have a role in the management of chronic, treatment refractory, major depressive and obsessive-compulsive disorders.²¹ Its practice needs to be restricted to a few specialist centres with rigorous preoperative assessment and outcome follow-up, and multicentre collaboration to facilitate comparative outcome studies of the effects of the different stereotactic lesions. Its application is likely to become even more restricted as advances in other psychiatric treatments progress. It is equally likely that in time a better understanding of the neurobiology of major depressive and obsessive-compulsive disorders and the accumulation of 'harder' outcome data will give NMD a stronger theoretical and empirical base. Finally, NMD in the future may not be restricted to making lesions in brain tissue. Transplantation into the human brain may eventually evolve into a viable form of treatment.

References

1. Moniz E. Tentatives opératoires dans le traitement de certaines psychoses. Paris: Masson, 1936.
2. Shuts D. Lobotomy. Resort to the Knife. New York: Van Nostrand Reinhold Co, 1982.
3. Freeman WJ, Watts J, Robinson MF. Psychosurgery: In the treatment of mental disorders and intractable pain. 2nd ed. Springfield: Charles C Thomas, 1950.
4. Swayze VW. Frontal leucotomy and related psychosurgical procedures in the era before antipsychotics (1935-1954): a historical review. *Am J Psychiatry* 1995; 152: 505-15.
5. Tooth GC, Newton MP. Leucotomy in England and Wales 1942-1954. Reports on public health and medical subjects. No.104, Ministry of Health, London: UNISO, 1961.
6. Fulton JF. Frontal lobotomy and affect: a neurophysiological analysis. New York: Norton WW, 1951.
7. Bridges PK, Bartlett JR, Hale AS, Poynton A, Malizia AL, Hodgkiss AD. Psychosurgery: stereotactic subcaudate tractotomy. An indispensable treatment. *Br J Psychiatry* 1994; 165: 599-611.
8. Mindus P, Rasmussen SA, Lindquist C. Neurosurgical treatment for refractory obsessive-compulsive disorder: implications for understanding frontal lobe function. *J Neuropsych Clin Neuroscience* 1994; 6: 467-77.
9. Baer L, Rauch SL, Ballantine HT et al. Cingulotomy for intractable obsessive-compulsive disorder: a prospective long-term follow-up of 18 patients. *Arch Gen Psychiatry* 1995; 52: 384-92.
10. Kitchen N. Neurosurgery for affective disorders at Atkinson Morley's Hospital 1948-1994. *Acta Neurochir Suppl (Wien)* 64: 64-8.
11. Hussain ES, Freeman H, Jones RAC. A cohort study of psychosurgery cases from a defined population. *J Neurol Neurosurg Psychiatry* 1988; 51: 345-52.
12. Hay P, Sachdev P, Cumming S et al. Treatment of obsessive-compulsive disorder by psychosurgery. *Acta Psychiatr Scand* 1993; 87: 197-202.
13. Mindus P, Nyrnan H. Normalisation of personality characteristics in patients with incapacitating anxiety disorders after capsulotomy. *Acta Psychiatr Scand* 1991; 83: 282-91.
14. Sachdev P and Hay P. Does neurosurgery for obsessive-compulsive disorder produce personality change? *J Nerv Ment Dis* 1995; 183: 408-13.
15. Kiloh LG, Smith JS, Johnson GF. Physical treatments in psychiatry. Melbourne: Blackwell Science, 1988: 277-333.
16. Kartsouris LD, Poynton A, Bridges PK, Bartlett JR. Neuropsychological correlates of stereotactic subcaudate tractotomy: a prospective study. *Brain* 1991; 114: 2657-73.
17. Neurosurgery for mental disorder. A report by a Good Practice Group of the CRAG Working Group on Mental Illness. The Scottish Office, Edinburgh: HMSO, 1996.
18. Bird JM, Crow CD. Psychosurgery in obsessive-compulsive disorder. In: Montgomery SA, Goodman WK, Goeting N, eds. Obsessive-compulsive disorder. Duphar Medical, 1990: 82-92.
19. Crow HJ. Controlled multifocal frontal leucotomy for psychiatric illness. *J Neurol Neurosurg Psychiatry* 1961; 24: 353-60.
20. Snaith RP. Psychosurgery: controversy and enquiry. *Br J Psychiatry* 1994; 165: 582-4.
21. Sachdev P, Sachdev J. Sixty years of psychosurgery: its present status and its future. *Aust NZ J Psychiatry* 1997; 31: 457-64.

THE IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

IS NOW ON LINE AT:
www.ijpm.org